AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback. At an ...
Most patients with alcohol-associated hepatitis (AH) have composite liver and alcohol-use events within 6 months, according to study results published in the journal Hepatology. T ...
Background and Purpose— Patent foramen ovale (PFO) has been identified as a potential risk factor for cerebrovascular ischemia. Procoagulant mutations may increase the risk and impact the choice of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback